Skip to main content
NCBI home page
The Journal of Headache and Pain logoLink to The Journal of Headache and Pain
. 2007 Oct 23;8(5):294–300. doi: 10.1007/s10194-007-0414-7

The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache

A Kemal Erdemoglu 1,✉, Ayhan Varlibas 1
PMCID: PMC3476152  PMID: 17955170

Abstract

The objective of this study was to investigate the long-term efficacy and safety of botulinum toxin type-A (BoNT-A) for refractory chronic tension-type headache (CTTH). An open-label, prospective study was carried out in the Department of Neurology of Kirikkale University on 28 patients (8 males, 20 females), mean age 35.6 years, diagnosed with moderate/severe CTTH refractory to preventive medications. Each patient received BoNT-A injections once in pericranial muscles. Efficacy and safety data were analysed for 28 refractory CTTH patients who were receiving concomitant headache prophylactic medications at baseline and during the study. The main outcome parameters were reduction of headache frequency and intensity over 1 year. Both parameters were significantly decreased (p<0.05) by the end of the study. Sixty-four percent of patients reported complete headache relief at the final visit, compared to 7% CTTH persisted. BoNT-A also resulted in significant reductions in analgesic consumption (p<0.05). Adverse effects were transient and local. BoNT-A was found to be an effective and safe treatment for refractory CTTH patients with concomitant headache prophylactic medications, resulting in significant reductions in headache frequency, intensity and analgesic consumption which persisted up to 1 year.

Keywords: Botulinum toxin type-A (BoNT-A), Chronic tension-type headache (CTTH), Headache frequency, Headache intensity, Refractory, Treatment

Full Text

The Full Text of this article is available as a PDF (408.3 KB).

References

  • 1.Mueller L. Tension-type, the forgotten headache. How to recognize this common but undertreated condition. Postgrad Med. 2002;111:25–26. doi: 10.3810/pgm.2002.04.1165. [DOI] [PubMed] [Google Scholar]
  • 2.Schulman E.A. Overview of tension-type headache. Curr Pain Headache Rep. 2001;5:454–462. doi: 10.1007/s11916-001-0057-3. [DOI] [PubMed] [Google Scholar]
  • 3.Cheung R.T.F. Prevalence of migraine, tension-type headache, and other headaches in Hong Kong. Headache. 2000;40:473–479. doi: 10.1046/j.1526-4610.2000.00071.x. [DOI] [PubMed] [Google Scholar]
  • 4.Gobel H., Petersen-Braun M., Soyka D. The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia. 1994;14:97–106. doi: 10.1046/j.1468-2982.1994.1402097.x. [DOI] [PubMed] [Google Scholar]
  • 5.Pryse-Phillips W., Findlay H., Tugwell P., et al. A Canadian population survey on the clinical, epidemiologic and societal impact of migraine and tension-type headache. Can J Neurol Sci. 1992;19:333–339. [PubMed] [Google Scholar]
  • 6.Rasmussen B.K., Jensen R., Schroll M., Olesen J. Epidemiology of headache in a general population — a prevalence study. J Clin Epidemiol. 1991;44:1147–1157. doi: 10.1016/0895-4356(91)90147-2. [DOI] [PubMed] [Google Scholar]
  • 7.Rasmussen B.K., Jensen R., Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Community Health. 1992;46:443–446. doi: 10.1136/jech.46.4.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Schwartz B.J., Stewart W.F., Simon D., Lipton R.B. Epidemiology of tension-type headache. JAMA. 1998;279:381–383. doi: 10.1001/jama.279.5.381. [DOI] [PubMed] [Google Scholar]
  • 9.Jensen K., Norup M. Experimental pain in human muscle induced by hypertonic saline, potassium and acidity. Cephalalgia. 1992;12:101–106. doi: 10.1046/j.1468-2982.1992.1202101.x. [DOI] [PubMed] [Google Scholar]
  • 10.Rollnik J.D., Karst M., Fink M., Dengler R. Coping strategies in episodic and chronic tension-type headache. Headache. 2001;41:297–302. doi: 10.1046/j.1526-4610.2001.111006297.x. [DOI] [PubMed] [Google Scholar]
  • 11.Holroyd K.A., Stensland M., Lipchik G.L., et al. Psychosocial correlates and impact of chronic tension-type headaches. Headache. 2000;40:3–16. doi: 10.1046/j.1526-4610.2000.00001.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Borodic G.E., Acquadro M., Johnson E.A. Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs. 2001;10:1531–1544. doi: 10.1517/13543784.10.8.1531. [DOI] [PubMed] [Google Scholar]
  • 13.Smuts J.A., Baker M.K., Smuts H.M., et al. Prophylactic treatment of chronic tension-type headache using botulinum toxin type A. Eur J Neurol. 1999;6(suppl4):S99–S102. doi: 10.1111/j.1468-1331.1999.tb00044.x. [DOI] [Google Scholar]
  • 14.Evers S., Vollmer-Haase J., Schwaag S., et al. Botulinum toxin A in the prophylactic treatment of migraine—a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24:838–843. doi: 10.1111/j.1468-2982.2004.00754.x. [DOI] [PubMed] [Google Scholar]
  • 15.Silberstein S., Mathew N., Saper J., Jenkins S. f., the BOTOX® Migraine Clinical Research Group Botulinum toxin type A as a migraine preventive treatment. Headache. 2000;40:445–450. doi: 10.1046/j.1526-4610.2000.00066.x. [DOI] [PubMed] [Google Scholar]
  • 16.Relja M.A. Treatment of tension-type headache by local injection of botulinum toxin. Euro J Neurol. 1997;4(Suppl2):71–72. [Google Scholar]
  • 17.Relja M.A. Treatment of tension-type headache with botulinum toxin: 1-year follow-up. Cephalalgia. 2000;20:336. [Google Scholar]
  • 18.Ondo W.G., Vuong K.D., Derman H.S. Botulinum toxin A for chronic daily headache: a randomized, place-bo-controlled, parallel design study. Cephalalgia. 2004;24:60–65. doi: 10.1111/j.1468-2982.2004.00641.x. [DOI] [PubMed] [Google Scholar]
  • 19.Schulte-Mattler W.J., Wieser T., Zierz S. Treatment of tensiontype headache with botulinum toxin: a pilot study. Eur J Med Res. 1999;4:183–186. [PubMed] [Google Scholar]
  • 20.Schmitt W.J., Slowey E., Fravi N., et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double blind, placebo-controlled trial. Headache. 2001;41:658–664. doi: 10.1046/j.1526-4610.2001.041007658.x. [DOI] [PubMed] [Google Scholar]
  • 21.Rollnik J.D., Tanneberger O., Schubert M., et al. Treatment of tension-type headache with botulinum toxin A: a double-blind, placebo-controlled study. Headache. 2000;40:300–305. doi: 10.1046/j.1526-4610.2000.00044.x. [DOI] [PubMed] [Google Scholar]
  • 22.Silberstein S.D., Göbel H., Jensen R., et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26:790–800. doi: 10.1111/j.1468-2982.2006.01114.x. [DOI] [PubMed] [Google Scholar]
  • 23.Burch C.M., Kokoska M.S., Glaser D.A., Hollenbeak C.S. Treatment of frontal tension headaches with botulinum toxin A. Cephalalgia. 2001;21:486–491. doi: 10.1046/j.1468-2982.2001.00030.x. [DOI] [Google Scholar]
  • 24.Relja M.A., Telarovic S. Botulinum toxin in tension-type headache. J Neurol. 2004;251(Suppl):1/12–1/14. doi: 10.1007/s00415-004-1104-x. [DOI] [PubMed] [Google Scholar]
  • 25.Mennini F.S., Fioravanti L., Piasini L., et al. A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache. J Headache Pain. 2004;5:188–191. doi: 10.1007/s10194-004-0099-5. [DOI] [Google Scholar]
  • 26.Farinelli I., Coloprisco G., Filippis S., Martelletti P. Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain. 2006;7:407–412. doi: 10.1007/s10194-006-0344-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mathew N., Frishberg B.M., Gawel M., et al. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293–307. doi: 10.1111/j.1526-4610.2005.05066.x. [DOI] [PubMed] [Google Scholar]
  • 28.Jensen R. Peripheral and central mechanisms in tension-type headache: an update. Cephalalgia. 2003;23(Suppl.1):49–52. doi: 10.1046/j.1468-2982.2003.00574.x. [DOI] [PubMed] [Google Scholar]
  • 29.Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache. 2003;43(suppl1):9–15. doi: 10.1046/j.1526-4610.43.7s.3.x. [DOI] [PubMed] [Google Scholar]
  • 30.Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–133. doi: 10.1016/j.pain.2003.10.008. [DOI] [PubMed] [Google Scholar]
  • 31.Durham P.L., Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache. 2004;44:35–42. doi: 10.1111/j.1526-4610.2004.04007.x. [DOI] [PubMed] [Google Scholar]
  • 32.Oshinsky M.L., Pozo-Rosich P., Luo J., et al. Botulinum toxin type A blocks sensitization of neurons in the trigeminal nucleus candalis. Cephalalgia. 2004;24:781. [Google Scholar]
  • 33.Mathew N. The Prophylactic Treatment of Chronic Daily Headache. Headache. 2006;46:1552–1564. doi: 10.1111/j.1526-4610.2006.00621.x. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Headache and Pain are provided here courtesy of BMC

RESOURCES